Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 7/2012

01.07.2012 | Review Article

An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors

verfasst von: Yin Ting Cheung, Earl Hsien-Jie Tan, Alexandre Chan

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The choice of appropriate neuropsychological tests is important in evaluating the onset, severity, duration, and site of cognitive changes in postchemotherapy breast cancer survivors. This literature review is designed to evaluate and provide a summary of suitable neuropsychological tests to determine cognitive changes in breast cancer survivors.

Method

A literature search restricted to publications in English before June 2011 was performed using the following combination of keywords: “neuropsychological assessments,” “breast cancer,” “chemotherapy,” and “cognitive impairment.” Only observational studies that performed cognitive assessments on breast cancer survivors were included. The neuropsychological assessments were grouped as “objective” (traditional batteries and screening tests), “subjective,” or “computerized.”

Results

Of the 43 studies extracted, memory (88 %) and attention/concentration (88 %) are the two most commonly assessed domains. A majority (63 %) employed the use of Wechsler Adult Intelligent Scale (an objective test), while only 49 % incorporated subjective assessments to assess perceived cognitive impairment. Computerized tests received low popularity (28 %) despite their numerous advantages, which include overcoming the language- and cultural-dependent limitations of traditional objective tests.

Conclusions

In the selection of a suitable neuropsychological tool to determine the onset, severity, site, and duration of cognitive changes in breast cancer survivors, incorporation of both subjective and objective tests is essential to facilitate a comprehensive assessment. With more validation work performed in future studies, it may be feasible to employ computerized neuropsychological assessments in both clinical and research settings.
Literatur
1.
Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708PubMedCrossRef
2.
Cheung YT, Shwe M, Tan YP, Fan G, Ng R, Chan A (2012) Cognitive changes in multiethnic Asian breast cancer patients: A focus group study. Ann Oncol. doi:10.​1093/​annonc/​MDS1029
3.
4.
Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice Cognitive Workshop. Ann Oncol 19:623–629PubMedCrossRef
5.
Vardy J, Tannock IF (2007) Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol 63:183–202PubMedCrossRef
6.
Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2010) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647–1656PubMedCrossRef
7.
Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J (2008) Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology 17:1189–1195PubMedCrossRef
8.
Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FSAM (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397PubMedCrossRef
9.
Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463PubMedCrossRef
10.
Hurria A, Lachs M (2007) Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer? Breast Cancer Res Treat 103:259–268PubMedCrossRef
11.
Pullens MJJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology 19:1127–1138PubMedCrossRef
12.
Phillips K-A, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95:190–197PubMedCrossRef
13.
Shilling V, Jenkins V, Trapala IS (2006) The (mis) classification of chemo-fog–methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95:125–129PubMedCrossRef
14.
Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967–982PubMedCrossRef
15.
Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2233PubMedCrossRef
16.
Strauss E, Sherman EMS, Otfried S (2006) A compendium of neuropsychological tests. Oxford University Press, New York
17.
Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander AR, Schulz-Kindermann F, Koch UT (2006) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415–423PubMedCrossRef
18.
Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, Zander AR, Koch U (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66:108–118PubMedCrossRef
19.
Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121:91–100PubMedCrossRef
20.
Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440PubMedCrossRef
21.
Mehlsen M, Pedersen AD, Jensen AB, Zachariae R (2009) No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology 18:248–257PubMedCrossRef
22.
Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psycho-Oncology 18:134–143PubMedCrossRef
23.
Reid-Arndt SA, Yee A, Perry MC, Hsieh C (2009) Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol 27:415–434PubMedCrossRef
24.
Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 15:422–430PubMedCrossRef
25.
Wechsler D (1955) Manual for the Wechsler Adult Intelligence Scale. Psychological Corporation, Oxford
26.
Rabin LA, Barr WB, Burton LA (2005) Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, and APA Division 40 members. Arch Clin Neuropsychol 20:33–65PubMedCrossRef
27.
Camara WJ, Nathan JS, Puente AE (2000) Psychological test usage: implications in professional psychology. Prof Psychol Res Pr 31:141–154
28.
Smith GE, Malec JF, Ivnik RJ (1992) Validity of the construct of nonverbal memory: a factor-analytic study in a normal elderly sample. J Clin Exp Neuropsychol 14:211–221PubMedCrossRef
29.
Lees-Haley PR, Greiffenstein MF, Larrabee GJ, Manning EL (2004) Methodological problems in the neuropsychological assessment of effects of exposure to welding fumes and manganese. Clin Neuropsychol 18:449–464PubMedCrossRef
30.
Flanagan DP, McGrew KS, Ortiz SO (2000) The Wechsler Intelligence Scales and Gf-Gc theory: a contemporary approach to interpretation. McGraw-Hill, Boston
31.
Hammes JGW (1978) De Stroop Kleur–Woord Test. Handleiding, Tweede Gewijzigde Druk. [The Stroop color-word test. Manual, 2nd edn]. Swets & Zeitlinger, Lisse
32.
Rey A (1941) L’Examen Psychologie dans Les Cas D’encephalopathie Traumatique. [The psychological examination in cases of traumatic encephalopathy]. Arch de Psychologie 23:286–228
33.
Reitan RM (1958) Validity of the Trail Making Test As An Indicator Of Organic Brain Damage. Percept Mot Skills 8:271–286
34.
Kulas JF, Axelrod BN (2002) Comparison of seven-subtest and Satz–Mogel short forms of the WAIS-III. J Clin Psychol 58:773–782PubMedCrossRef
35.
Ryan JJ, Lopez SJ, Werth TR (1999) Development and preliminary validation of a Satz–Mogel short form of the WAIS-III in a sample of persons with substance abuse disorders. Int J Neurosci 98:131–140PubMedCrossRef
36.
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef
37.
Randolph C, Tierney MC, Mohr E, Chase TN (1998) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20:310–319PubMedCrossRef
38.
Faust D, Fogel BS (1989) The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 177:25–31PubMedCrossRef
39.
Vardy J, Wong K, Yi Q-L, Park A, Maruff P, Wagner L, Tannock IF (2006) Assessing cognitive function in cancer patients. Support Care Cancer 14:1111–1118PubMedCrossRef
40.
Tchen N, Juffs HG, Downie FP, Yi Q-L, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183PubMedCrossRef
41.
Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMed
42.
Noal S, Levy C, Hardouin A, Rieux C, Heutte N, Segura C, Collet F, Allouache D, Switsers O, Delcambre C, Delozier T, Henry-Amar M, Joly F (2010) One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 81:795–803PubMedCrossRef
43.
Minisini AM, De Faccio S, Ermacora P, Andreetta C, Fantinel R, Balestrieri M, Piga A, Puglisi F (2008) Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 67:71–79PubMedCrossRef
44.
Iconomou G, Mega V, Koutras A, Iconomou AV, Kalofonos HP (2004) Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy. Cancer 101:404–411PubMedCrossRef
45.
Yamada TH, Denburg NL, Beglinger LJ, Schultz SK (2010) Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 22:48–54PubMedCrossRef
46.
Elwood DL, Griffin HR (1972) Individual intelligence testing without the examiner: reliability of an automated method. J Consult Clin Psychol 38:9–14CrossRef
47.
48.
Fray PJ, Robbins TW (1996) CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol 18:499–504PubMedCrossRef
49.
Erlanger DM, Kaushik T, Broshek D, Freeman J, Feldman D, Festa J (2002) Development and validation of a web-based screening tool for monitoring cognitive status. J Head Trauma Rehabil 17:458–476PubMedCrossRef
50.
Homack S, Riccio CA (2006) Conners’ continuous performance test (2nd edn; CCPT-II). J Atten Disord 9:556–558PubMedCrossRef
51.
Feldstein SN, Keller FR, Portman RE, Durham RL, Klebe KJ, Davis HP (1999) A comparison of computerized and standard versions of the Wisconsin Card Sorting Test. Clin Neuropsychol 13:303–313PubMedCrossRef
52.
Gonzalez R, Heaton RK, Moore DJ, Letendre S, Ellis RJ, Wolfson T, Marcotte T, Cherner M, Rippeth J, Grant I (2003) Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 9:64–71PubMedCrossRef
53.
Miller EN, Satz P, Visscher B (1991) Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men. Neurology 41:1608–1616PubMedCrossRef
54.
Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21(Pt 1):1–16PubMedCrossRef
55.
Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A (1994) Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 16:93–104PubMedCrossRef
56.
Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123PubMedCrossRef
57.
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969PubMedCrossRef
58.
Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11:6–15PubMedCrossRef
59.
Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G, Shah E, Stein R, Whitehead S, Winstanley J (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834PubMedCrossRef
60.
Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Smeets A, Christiaens MR, Leemans A, Van Hecke W, Vandenberghe J, Vandenbulcke M, Sunaert S (2011) Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 32:480–493PubMedCrossRef
61.
Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104:2499–2507PubMedCrossRef
62.
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA (2007) Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25:3866–3870PubMedCrossRef
63.
Jim HSL, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:1776–1783PubMedCrossRef
64.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F (1993) The European Organisation for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in International clinical trials in oncology. J Natl Cancer Inst 85:365–376
65.
Ruzich M, Ryan B, Owen C, Delahunty A, Stuart-Harris R (2007) Prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy. Asia Pac J Clin Oncol 3:123–133CrossRef
66.
Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FSAM (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51:159–165PubMedCrossRef
67.
van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218PubMedCrossRef
68.
Skaali T, Foss SD, Dahl AA (2011) A prospective study of cognitive complaints in patients with testicular cancer. Clin Genitourin Cancer 9:6–13PubMedCrossRef
69.
Gan HK, Bernstein LJ, Brown J, Ringash J, Vakilha M, Wang L, Goldstein D, Kim J, Hope A, O’Sullivan B, Waldron J, Abdul Razak AR, Chen EX, Siu LL (2011) Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 81:126–134PubMedCrossRef
70.
Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IGH, Schlegel U (2010) Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 67:182–189PubMedCrossRef
71.
Taillibert S, Voillery D, Bernard-Marty C (2007) Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 19:623–627PubMedCrossRef
72.
Schatz P, Browndyke J (2002) Applications of computer-based neuropsychological assessment. J Head Trauma Rehabil 17:395–410PubMedCrossRef
73.
Saykin AJ, Ahles TA, McDonald BC (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8:201–216PubMedCrossRef
74.
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819–828PubMedCrossRef
75.
Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YKK, Fang Y, Golden CR, Frosch ME, Habif U, Mulligan MM, Chen IS, Hershman DL (2010) The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 123:25–34PubMedCrossRef
76.
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356PubMedCrossRef
77.
Biglia N, Moggio G, Peano E, Sgandurra P, Ponzone R, Nappi RE, Sismondi P (2010) Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 7:1891–1900PubMedCrossRef
78.
Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962PubMedCrossRef
79.
Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913PubMedCrossRef
80.
Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF (2006) Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 15:921–930PubMedCrossRef
81.
Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA (2004) ‘Chemobrain’ in breast carcinoma?: a prologue. Cancer 101:466–475PubMedCrossRef
82.
Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedCrossRef
83.
Servaes P, Verhagen CA, Bleijenberg G (2002) Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior. Cancer 95:2017–2026PubMedCrossRef
84.
Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4:61–66CrossRef
85.
Kreukels BP, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB (2008) Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 8:80–87PubMedCrossRef
86.
Gottschalk LA, Holcombe RF, Jackson D, Bechtel RJ (2003) The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol 25:117–122PubMedCrossRef
87.
Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650PubMedCrossRef
88.
Falleti MG, Maruff P, Collie A, Darby DG (2006) Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test–retest intervals. J Clin Exp Neuropsychol 28:1095–1112PubMedCrossRef
89.
French CC, Beaumont JG (1987) The reaction of psychiatric patients to computerized assessment. Br J Clin Psychol 26:267–278PubMedCrossRef
90.
Collie A, Maruff P, McStephen M, Darby DG (2003) Psychometric issues associated with computerised neuropsychological assessment of concussed athletes. Br J Sports Med 37:556–559PubMedCrossRef
91.
92.
Collie A, Maruff P, Makdissi M, McCrory P, McStephen M, Darby D (2003) CogSport: reliability and correlation with conventional cognitive tests used in postconcussion medical evaluations. Clin J Sport Med 13:28–32PubMedCrossRef
93.
Conners CK, Staff M (2000) Conners’ Continuous Performance Test (CPT II) computer programs for Windows technical guide and software manual. Multi-Health Systems, North Tonawanda
94.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
95.
Cimprich B, Visovatti M, Ronis DL (2011) The Attentional Function Index—a self-report cognitive measure. Psycho-Oncology 20:194–202PubMedCrossRef
96.
Goldberg D, Williams P (1988) A user’s guide to the general health questionnaire. NFER-Nelson, Windsor
97.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
98.
Duff K, Beglinger LJ, Schoenberg MR, Patton DE, Mold J, Scott JG, Adams RL (2005) Test–retest stability and practice effects of the RBANS in a community dwelling elderly sample. J Clin Exp Neuropsychol 27:565–575PubMedCrossRef
99.
Nelson HE (1982) National Adult Reading Test (NART): test manual. NFER Nelson, Windsor
100.
Blair JR, Spreen O (1989) Predicting premorbid IQ: a revision of the National Adult Reading Test. Clin Neuropsychol 3:129–136
101.
Crawford JR, Stewart LE, Besson JAO, Parker DM, De Lacey G (1989) Prediction of WAIS IQ with the National Adult reading test: Cross-validation and extension. Br J Clin Psychol 28:267–273
102.
Raguet ML, Campbell DA, Berry DTR, Schmitt FA, Smith GT (1996) Stability of intelligence and intellectual predictors in older persons. Psychol Assess 8: 154–160
103.
Mitrushina M, Satz P (1991) Effect of repeated administration of a neuropsychological battery in the elderly. J Clin Psychol 47:790–801PubMedCrossRef
104.
Shapiro AM, Benedict RH, Schretlen D, Brandt J (1999) Construct and concurrent validity of the Hopkins Verbal Learning Test—revised. Clin Neuropsychol 13:348–358PubMedCrossRef
105.
Kaplan EF, Goodglass H, Weintraub S (2001) The Boston naming test, 2nd edn. Lippincott Williams & Wilkins, Philadelphia
106.
Flanagan JL, Jackson ST (1997) Test–retest reliability of three aphasia tests: performance of non-brain-damaged older adults. J Commun Disord 30:33–42PubMedCrossRef
107.
Mitrushina M, Satz P (1995) Repeated testing of normal elderly with the Boston naming test. Aging 7:123–127
108.
Ross TP, Calhoun E, Cox T, Wenner C, Kono W, Pleasant M (2007) The reliability and validity of qualitative scores for the Controlled Oral Word Association Test. Arch Clin Neuropsychol 22:475–488PubMedCrossRef
Metadaten
Titel
An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors
verfasst von
Yin Ting Cheung
Earl Hsien-Jie Tan
Alexandre Chan
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1445-4

Weitere Artikel der Ausgabe 7/2012

Supportive Care in Cancer 7/2012 Zur Ausgabe

Original Article

Examining the role of physical activity in reducing postcancer fatigue

Original Article

Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy

Original Article

Psychotropic medication during endocrine treatment for breast cancer

Review Article

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

Original Article

Physician endorsement alone may not enhance question-asking by advanced cancer patients during consultations about palliative care

Short Communication

Lenalidomide cutaneous adverse event: a case of Stevens–Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise